Could a common pain reliever boost a cancer drug? early trial underway
NCT ID NCT04640779
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope that adding choline salicylate might allow a lower, less toxic dose of selinexor while still fighting the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selinexor and choline salicylate
- What this could lead to
- If this combination works, it could offer a new treatment option for patients with certain lymphomas or multiple myeloma that have not responded to prior therapy.
- What could go wrong
- This is a very early phase 1 trial with only 22 participants, so it is mainly looking at safety and dosing, not yet proving effectiveness. The combination may cause side effects or may not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT HISTIOCYTIC AND DENDRITIC CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy shows promise for tough lymphoma cases
- Double-Barreled attack: stem cell transplant plus CAR-T shows promise for Hard-to-Treat lymphoma
- Supercharged immune cells take on tough lymphoma
- Triple-Target CAR T-Cells offer new hope for tough blood cancers
- Blood cancer transplant study tests safer GVHD prevention
- Can a weekly drug combo outsmart resistant lymphoma?